Drug discovery and development firm Viamet Pharmaceuticals has named a new top financial executive as the company readies two clinical stage compounds for potential drug partners. Dr. Richard Katz was ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VT-1129 for the ...
Viamet Pharmaceuticals has registered an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were listed in the filing, but ...
With a $60 million shot in the arm, Durham's Viamet Pharmaceuticals can develop anti-fungal treatments out of the scrutiny of public markets, giving its scientists and executives leeway to focus on ...
Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life ...
Viamet Pharmaceuticals, a biotech developing metal-binding protein therapeutics to treat fungal diseases, withdrew its plans for an initial public offering on Monday. On Tuesday, the company announced ...
Instead of entering the publicly traded realm, Durham's Viamet Pharmaceuticals was able to raise $60 million in private money, an to give the company a two-year cash runway, according to company ...
Company to Advance Development of Novel Metalloenzyme Inhibitors and Proprietary Metallophile TM Technology Platform RESEARCH TRIANGLE PARK, N.C. -- Viamet Pharmaceuticals, Inc. announced today that ...
RESEARCH TRIANGLE PARK, N.C., Oct 21, 2014 (BUSINESS WIRE) -- Viamet Pharmaceuticals Holdings, LLC (Viamet) today announced the closing of a $60 million Series D financing provided by Brandon Point ...
Viamet Pharmaceuticals Holdings LLC, which withdrew plans for an initial public offering a year and a half ago, has set an estimated price range for its current bid to go public. The Durham, N.C., ...
Viamet Pharmaceuticals Holdings LLC pulled its plans for an initial public offering, according to a filing with the Securities and Exchange Commission late Friday. In a statement, Viamet said it “has ...
Viamet Pharmaceuticals has filed an initial public offering for up to $100 million worth of shares. The North Carolina-based drug maker has researched and developed antifungal drugs. "We have applied ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results